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We would like to welcome all participants of the 6th
Cachexia Conference in Milan, which takes place from
December 8 to 10, 2011. The constantly growing number of
participants who come from more than 27 countries shows
that the meeting is well-received throughout the globe
(Fig. 1). The conference provides an important opportunity
to share and exchange knowledge in a vast number of fields
in the area of cachexia and body wasting in many different
illnesses. In addition, the meeting covers pathophysiolog-
ical and biochemical aspects of cachexia and wasting
disorders, but also the field of sarcopenia that receives
increasing research efforts over the last several years. Thus,
the Cachexia Conference provides a rare opportunity for
exchange between basic researchers and clinicians.
This year, all 155 abstracts submitted for evaluation and
accepted for presentation until end of September 2011 are
included in this issue of the Journal of Cachexia,
Sarcopenia and Muscle (JCSM). Abstracts accepted later
will be printed in the first issue of 2012. Also, the number
of abstracts has substantially increased since the initial
conference (Fig. 1), and as you will see during the
conference in Milan, an increased amount of space and
time is given to poster discussions.
The first issue of JCSM has been published in September
2010. JCSM is published quarterly as a hard copy journal as
well as on an open-access basis without page charges for
authors. All submitted articles are undergoing peer review.
In April 2011, after appearance of only its third issue,
JCSM was accepted for indexing in PubMed®. We are
proud to say that all issues of JCSM are included in
PubMed® and can be downloaded free of charge from
PubMed Central as well as from the journal’s dedicated
websites at www.jcsm.info and www.jcsm.springer.de.
Since publication of the first issue of JCSM, three double-
blind, randomized, placebo-controlled trials covering differ-
ent aspects and therapeutic approaches to cachexia, have
been included in the journal [1–3]. In addition, the rationale
and design of two clinical studies (one a registry and the
other a phase II clinical trial) have also been published in
JCSM [4, 5]. We invite everyone to follow this example.
Please help us to make JCSM the premier journal to read
about dedicated treatment and prevention studies in the fields
of cachexia and sarcopenia. According to Google Scholar,
the total number of citations of all 12 articles published in
2010 alone sums up to 104 [6]. Therefore, authors
submitting to JCSM have a high likelihood of broad
awareness of their results.
We were horrified when we learned about the tragic
events in Fukushima and its surroundings that ultimately
forced us to re-schedule our meeting. Our thoughts are with
our Japanese colleagues and their families. We also
sincerely hope that our next meeting in December 2013
can successfully take place in Kobe/Japan as originally
planned for this year.
But now we are in Milan and we want to sincerely thank
the local organizers, the society staff and all our supporters
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conference possible. We wish all participants of the 6th
Cachexia Conference an interesting and stimulating meet-
ing and hope to meet up during the sessions, the poster
discussions, or at one of the evening events. Many of you
will be contacted to submit original papers and/or reviews
to our journal. Only through the exchange of ideas and
scientific research results we can ultimately achieve what
this is all about—improve the lives of our patients.
Cachexia, sarcopenia, and muscle wasting are big medical
needs, and you and your publications are a seminal
building stone of future therapeutic successes. Please
f e e li n v i t e dt os u b m i ty o u rw o r kt oJCSM.W ep r o m i s e ,
we will give it our undivided attention and turn around
your manuscripts fast.
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Fig. 1 Number of participants and of accepted abstracts at the
Cachexia Conferences in Berlin, Germany (2000 and 2003), Rome,
Italy (2005), Tampa, Florida (2007), and Barcelona, Spain (2009)
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